synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-15. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
It may replace glucose in many chemical reactions due to its similarity in structure, may prevent the non-enzymatic glycosylation of proteins, and might reduce glycated hemoglobin (HbA1c) levels. Secondly, vitamin C has also been suggested to play a role in lipid regulation as a controlling catabolism of cholesterol to bile acid.
=== Economic reforms === The FSN had to choose between the two economic models that political elites claimed were available to post-Communist Eastern European countries: shock therapy or gradual reforms. The FSN chose the latter, slower reforms, because it would have not been possible to convince the people who were already "exhausted" after Ceaușescu's austerity to undergo further sacrifices. Nevertheless, neoliberal reforms were implemented, although not all at once: by the end of 1990, prices were liberalised and a free currency exchange rate was implemented, devaluing the leu by 60%. The land of the state-owned collective farms was distributed to private owners and a list of 708 large state-owned enterprises to be privatised was devised. In 1991 Romania signed an agreement with the IMF and began the privatisation of state-owned enterprises, with the first privatisation law being passed in 1991. In 1992, the Stolojan government began an austerity plan, limiting wages and further liberalising prices. The economic situation deteriorated and inflation as well as unemployment increased substantially. The austerity measures, which by 1995 included a decrease in social spending, led to an increase in poverty. The neoliberal reforms were accelerated after the Democratic Convention won the 1996 elections, the government using its prerogatives to pass a package of laws, removing subsidies, passing reforms on unemployment benefits and greatly increasing the number of privatised companies.
The balance of threat theory is an offshoot of neorealism, coined in 1985 by Stephen M. Walt in an attempt to explain why balancing against rising hegemons has not always been consistent in history. In contrast to traditional balance of power theorists, Walt suggests that states balance against threats, rather than against power alone. The "balance-of-power theory is not wrong; it is merely incomplete. Power is one of the factors that affect the propensity to balance, although it is not the only one nor always the most important." The theory acknowledges that power is an extremely important factor in the level of threat posed by a state, but also includes geographic proximity, offensive capabilities, and perceived intentions. Balance of threat theory is an interesting adjunct to neorealism, because as a structural theory, neorealism only predicts that balances of power will form, not whether a particular state will balance or bandwagon (inter alia), or which state it might balance with. As Waltz put it: "balance of power theory is often criticized because it does not explain the particular policies of states. True, the theory does not tell us why state X made a certain move last Tuesday. To expect it to do so would be like expecting the theory of universal gravitation to explain the wayward pattern of a falling leaf.
The County of Schaumburg (not to be confused with the Principality of Schaumburg-Lippe) around the towns of Rinteln and Hessisch Oldendorf did indeed belong to the Prussian province of Hesse-Nassau until 1932, a province that also included large parts of the present state of Hesse, including the cities of Kassel, Wiesbaden and Frankfurt am Main; but in 1932 the County of Schaumburg became part of the Prussian Province of Hanover. When the Nazi Party seized power in 1933, they quickly transformed Germany into a highly centralised state and divided the entire Third Reich into Gaue which largely superseded (but did not outright replace) Germany's traditional federal system. Nevertheless, some changes to the old state and provincial borders were made in 1937, notably including the city of Cuxhaven being fully integrated into the Prussian Province of Hanover under the Greater Hamburg Act. The effect of this Nazi-era change was that in 1946, after the Third Reich had collapsed and when state of Lower Saxony was founded, only four states needed to be merged. With the exception of Bremen and the areas that were ceded to the Soviet Occupation Zone in 1945, all those areas allocated to the new state of Lower Saxony in 1946, had already been merged into the "Constituency Association of Lower Saxony" in 1920.
Sources: en.wikipedia.org
Counter-Strike: Source retains its team-based objective-oriented first-person shooter style gameplay. The aim of playing a map is to accomplish a map's objective: defusing the bomb, rescuing all hostages, or killing the entire opposing team. The ultimate goal of the game is to win more rounds than the opposing team. Once players are killed, they do not respawn until the next round, though this depends on which server people play on. This gameplay feature distinguishes Counter-Strike from other first-person shooter games, where players respawn instantly or after a short delay. Shooting while moving dramatically decreases accuracy, and holding the trigger down to continuously shoot produces severe recoil. The severity of damage induced by weaponry is dependent upon the specific locations of hits, with hits to the head being most lethal and shots which make contact elsewhere causing lesser loss of health. Damage is also affected by the distance, and if the target wears protection.
Alpha particles were first described in the investigations of radioactivity by Ernest Rutherford in 1899, and by 1907 they were identified as He2+ ions. By 1928, George Gamow had solved the theory of alpha decay via tunneling. The alpha particle is trapped inside the nucleus by an attractive nuclear potential well and a repulsive electromagnetic potential barrier. Classically, it is forbidden to escape, but according to the (then) newly discovered principles of quantum mechanics, it has a tiny (but non-zero) probability of "tunneling" through the barrier and appearing on the other side to escape the nucleus. Gamow solved a model potential for the nucleus and derived, from first principles, a relationship between the half-life of the decay, and the energy of the emission, which had been previously discovered empirically and was known as the Geiger–Nuttall law.
== Second round proper == The draw for the second round was made on BBC Two on 7 November 2022 by Jermaine Beckford and Mickey Thomas at the Racecourse Ground in Wrexham, and consisted of the 40 winners from the previous round. The round contained one team from the seventh tier, Alvechurch, who defeated EFL League One club Cheltenham Town in the first round.
Sources: en.wikipedia.org
=== Low et al 2007 === Low, Wai Yee; Ng, Hooi Ling; Morton, Craig J.; Parker, Michael W.; Batterham, Philip; Robin, Charles (2007). "Molecular Evolution of Glutathione S-Transferases in the Genus Drosophila". Genetics. 177 (3). Genetics Society of America/Oxford University Press (OUP): 1363–1375. doi:10.1534/genetics.107.075838. ISSN 0016-6731. PMC 2147980. PMID 18039872.
==== MeSH E05.200.500 – cytological techniques ==== MeSH E05.200.500.105 – autoradiography MeSH E05.200.500.195 – cell count MeSH E05.200.500.195.107 – blood cell count MeSH E05.200.500.195.107.330 – erythrocyte count MeSH E05.200.500.195.107.330.725 – reticulocyte count MeSH E05.200.500.195.107.595 – leukocyte count MeSH E05.200.500.195.107.595.500 – lymphocyte count MeSH E05.200.500.195.107.595.500.150 – cd4 lymphocyte count MeSH E05.200.500.195.107.595.500.150.160 – cd4-cd8 ratio MeSH E05.200.500.195.107.740 – platelet count MeSH E05.200.500.195.870 – sperm count MeSH E05.200.500.251 – cell fractionation MeSH E05.200.500.307 – cell fusion MeSH E05.200.500.363 – cell separation MeSH E05.200.500.363.285 – cytapheresis MeSH E05.200.500.363.285.570 – leukapheresis MeSH E05.200.500.363.285.790 – plateletpheresis MeSH E05.200.500.363.400 – immunomagnetic separation MeSH E05.200.500.363.540 – leukocyte reduction procedures MeSH E05.200.500.383 – colony-forming units assay MeSH E05.200.500.383.910 – tumor stem cell assay MeSH E05.200.500.385 – cytogenetic analysis MeSH E05.200.500.385.130 – chromosome banding MeSH E05.200.500.385.500 – mitotic index MeSH E05.200.500.386 – cytophotometry MeSH E05.200.500.386.350 – flow cytometry MeSH E05.200.500.386.400 – image cytometry MeSH E05.200.500.386.400.500 – laser scanning cytometry MeSH E05.200.500.387 – diffusion chambers, culture MeSH E05.200.500.388 – drug screening assays, antitumor MeSH E05.200.500.388.930 – tumor stem cell assay MeSH E05.200.500.410 – electroporation MeSH E05.200.500.607 – histocytochemistry MeSH E05.200.500.607.512 – immunohistochemistry MeSH E05.200.500.607.790 – periodic acid-schiff reaction MeSH E05.200.500.607.810 – prussian blue reaction MeSH E05.200.500.620 – histocytological preparation techniques MeSH E05.200.500.620.530 – microtomy MeSH E05.200.500.620.530.160 – cryoultramicrotomy MeSH E05.200.500.620.530.160.260 – frozen sections MeSH E05.200.500.620.620 – replica techniques MeSH E05.200.500.620.620.150 – corrosion casting MeSH E05.200.500.620.620.260 – freeze fracturing MeSH E05.200.500.620.620.260.400 – freeze etching MeSH E05.200.500.620.670 – staining and labeling MeSH E05.200.500.620.670.130 – chromosome banding MeSH E05.200.500.620.670.325 – in situ hybridization MeSH E05.200.500.620.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.500.620.670.325.350.125 – chromosome painting MeSH E05.200.500.620.670.325.680 – primed in situ labeling MeSH E05.200.500.620.670.520 – negative staining MeSH E05.200.500.620.670.620 – periodic acid-schiff reaction MeSH E05.200.500.620.670.660 – prussian blue reaction MeSH E05.200.500.620.670.770 – shadowing (histology) MeSH E05.200.500.620.670.780 – silver staining MeSH E05.200.500.620.720 – tissue embedding MeSH E05.200.500.620.720.610 – paraffin embedding MeSH E05.200.500.620.720.640 – plastic embedding MeSH E05.200.500.620.760 – tissue preservation MeSH E05.200.500.620.760.160 – cryopreservation MeSH E05.200.500.620.760.160.260 – freeze drying MeSH E05.200.500.620.760.160.260.270 – freeze substitution MeSH E05.200.500.620.760.720 – tissue fixation MeSH E05.200.500.695 – karyometry MeSH E05.200.500.800 – patch-clamp techniques
The mild acidic and chemoselective post Ugi activation of 5 involving simultaneous indolamide formation and tert-butoxycarbonyl (Boc) removal gives the active amide 6 which allows cyclization to 7 without affecting other peptidic or even ester moieties and with stereochemical retention of the chiral centers.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.